mTOR inhibitors in the treatment of cancer

被引:108
作者
Fasolo, Angelica [1 ]
Sessa, Cristiana [1 ,2 ]
机构
[1] Ist Nazl Tumori, I-20133 Milan, Italy
[2] Oncol Inst So Switzerland, Bellinzona, Switzerland
关键词
deforolimus; everolimus; mammalian target of rapamycin; sirolimus; temsirolimus;
D O I
10.1517/13543784.17.11.1717
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The mammalian target of rapamycin (mTOR) is a protein kinase of the phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway with a central role in the control of cell proliferation, survival, mobility and angiogenesis. Dysregulation of mTOR pathway has been found in many human tumours; therefore, the mTOR pathway is considered an important target for the development of new anticancer drugs. Objective: To review the mTOR pathway, the role of the mTOR inhibitors in cancer treatment, the preclinical features and clinical results of the three mTOR inhibitors currently in development, temsirolimus, everolimus and deforolimus. Methods: Review of the published literature (abstracts, full papers) since 1995 on mTOR pathway and related pathway signalling, rapamycin and analogues. Results/conclusion: With each of the three mTOR inhibitors temsirolimus (CCI-779), everolimus (RAD001) and deforolimus (AP23573), a safe schedule of treatment has been defined and promising results of antitumour activity have been achieved in a variety of solid tumours, thus confirming the preclinical expectations.
引用
收藏
页码:1717 / 1734
页数:18
相关论文
共 104 条
[31]  
Grünwald V, 2002, CANCER RES, V62, P6141
[32]   Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].
Guba, M ;
von Breitenbuch, P ;
Steinbauer, M ;
Koehl, G ;
Flegel, S ;
Hornung, M ;
Bruns, CJ ;
Zuelke, C ;
Farkas, S ;
Anthuber, M ;
Jauch, KW ;
Geissler, EK .
NATURE MEDICINE, 2002, 8 (02) :128-135
[33]   Upstream and downstream of mTOR [J].
Hay, N ;
Sonenberg, N .
GENES & DEVELOPMENT, 2004, 18 (16) :1926-1945
[34]  
HEISEN HJ, 2003, NEW ENGL J MED, V349, P847
[35]   TOR1 AND TOR2 ARE STRUCTURALLY AND FUNCTIONALLY SIMILAR BUT NOT IDENTICAL PHOSPHATIDYLINOSITOL KINASE HOMOLOGS IN YEAST [J].
HELLIWELL, SB ;
WAGNER, P ;
KUNZ, J ;
DEUTERREINHARD, M ;
HENRIQUEZ, R ;
HALL, MN .
MOLECULAR BIOLOGY OF THE CELL, 1994, 5 (01) :105-118
[36]  
HESS G, 2008, J CLIN ONCOL, V26
[37]   A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer [J].
Hidalgo, Manuel ;
Buckner, Jan C. ;
Erlichman, Charles ;
Pollack, Marilyn S. ;
Boni, Joseph P. ;
Dukart, Gary ;
Marshall, Bonnie ;
Speicher, Lisa ;
Moore, Laurence ;
Rowinsky, Eric K. .
CLINICAL CANCER RESEARCH, 2006, 12 (19) :5755-5763
[38]  
Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295
[39]  
Huang SL, 2001, CANCER RES, V61, P3373
[40]   Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].
Hudes, Gary ;
Carducci, Michael ;
Tomczak, Piotr ;
Dutcher, Janice ;
Figlin, Robert ;
Kapoor, Anil ;
Staroslawska, Elzbieta ;
Sosman, Jeffrey ;
McDermott, David ;
Bodrogi, Istvan ;
Kovacevic, Zoran ;
Lesovoy, Vladimir ;
Schmidt-Wolf, Ingo G. H. ;
Barbarash, Olga ;
Gokmen, Erhan ;
O'Toole, Timothy ;
Lustgarten, Stephanie ;
Moore, Laurence ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281